Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Histopathological criteria and selection algorithms for BRCA1 genetic testing.

Gadzicki D, Schubert A, Fischer C, Milde S, Lehmann U, Steinemann D, Lück HJ, Kreipe H, Schlegelberger B.

Cancer Genet Cytogenet. 2009 Mar;189(2):105-11. doi: 10.1016/j.cancergencyto.2008.11.003.

PMID:
19215791
2.

Breast tumor immunophenotype of BRCA1-mutation carriers is influenced by age at diagnosis.

Vaziri SA, Krumroy LM, Elson P, Budd GT, Darlington G, Myles J, Tubbs RR, Casey G.

Clin Cancer Res. 2001 Jul;7(7):1937-45.

3.

HER-2/neu status and tumor morphology of invasive breast carcinomas in Ashkenazi women with known BRCA1 mutation status in the Ontario Familial Breast Cancer Registry.

Quenneville LA, Phillips KA, Ozcelik H, Parkes RK, Knight JA, Goodwin PJ, Andrulis IL, O'Malley FP.

Cancer. 2002 Nov 15;95(10):2068-75.

4.

Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer.

Atchley DP, Albarracin CT, Lopez A, Valero V, Amos CI, Gonzalez-Angulo AM, Hortobagyi GN, Arun BK.

J Clin Oncol. 2008 Sep 10;26(26):4282-8. doi: 10.1200/JCO.2008.16.6231.

PMID:
18779615
5.

Pathological features and BRCA1 mutation screening in premenopausal breast cancer patients.

Chang J, Hilsenbeck SG, Sng JH, Wong J, Ragu GC.

Clin Cancer Res. 2001 Jun;7(6):1739-42.

6.

BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: a population-based study.

Musolino A, Bella MA, Bortesi B, Michiara M, Naldi N, Zanelli P, Capelletti M, Pezzuolo D, Camisa R, Savi M, Neri TM, Ardizzoni A.

Breast. 2007 Jun;16(3):280-92. Epub 2007 Jan 25.

PMID:
17257844
7.

Cyclin D1 expression analysis in familial breast cancers may discriminate BRCAX from BRCA2-linked cases.

Colombo M, Giarola M, Mariani L, Ripamonti CB, De Benedetti V, Sardella M, Losa M, Manoukian S, Peissel B, Pierotti MA, Pilotti S, Radice P.

Mod Pathol. 2008 Oct;21(10):1262-70. doi: 10.1038/modpathol.2008.43. Epub 2008 Mar 7.

8.

A comparison of bilateral breast cancers in BRCA carriers.

Weitzel JN, Robson M, Pasini B, Manoukian S, Stoppa-Lyonnet D, Lynch HT, McLennan J, Foulkes WD, Wagner T, Tung N, Ghadirian P, Olopade O, Isaacs C, Kim-Sing C, Møller P, Neuhausen SL, Metcalfe K, Sun P, Narod SA.

Cancer Epidemiol Biomarkers Prev. 2005 Jun;14(6):1534-8.

9.

Mutation analysis of BRCA1 and BRCA2 from 793 Korean patients with sporadic breast cancer.

Han SH, Lee KR, Lee DG, Kim BY, Lee KE, Chung WS.

Clin Genet. 2006 Dec;70(6):496-501.

PMID:
17100994
10.

Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type.

Foulkes WD, Metcalfe K, Sun P, Hanna WM, Lynch HT, Ghadirian P, Tung N, Olopade OI, Weber BL, McLennan J, Olivotto IA, Bégin LR, Narod SA.

Clin Cancer Res. 2004 Mar 15;10(6):2029-34.

11.

BRCA1 expression in invasive breast carcinomas and clinicopathological correlations.

Comănescu M, Popescu CF.

Rom J Morphol Embryol. 2009;50(3):419-24.

12.

Major improvement in the efficacy of BRCA1 mutation screening using morphoclinical features of breast cancer.

Lidereau R, Eisinger F, Champème MH, Noguès C, Bièche I, Birnbaum D, Pallud C, Jacquemier J, Sobol H.

Cancer Res. 2000 Mar 1;60(5):1206-10.

13.

Immunohistochemical expression of BRCA1 protein in invasive ductal carcinoma of the breast.

Burkadze G, Khardzeishvili O, Gudadze M, Tsikhiseli G, Turashvili G.

Georgian Med News. 2010 Jul-Aug;(184-185):51-60.

PMID:
20834076
14.

Clinical and pathological features of BRCA1 associated carcinomas in a hospital-based sample of Dutch breast cancer patients.

de Bock GH, Tollenaar RA, Papelard H, Cornelisse CJ, Devilee P, van de Vijver MJ.

Br J Cancer. 2001 Nov 2;85(9):1347-50.

15.

Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study.

Fostira F, Tsitlaidou M, Papadimitriou C, Pertesi M, Timotheadou E, Stavropoulou AV, Glentis S, Bournakis E, Bobos M, Pectasides D, Papakostas P, Pentheroudakis G, Gogas H, Skarlos P, Samantas E, Bafaloukos D, Kosmidis PA, Koutras A, Yannoukakos D, Konstantopoulou I, Fountzilas G.

Breast Cancer Res Treat. 2012 Jul;134(1):353-62. doi: 10.1007/s10549-012-2021-9. Epub 2012 Mar 21.

PMID:
22434525
16.

BRCA1 germline mutations and tumor characteristics in Chinese women with familial or early-onset breast cancer.

Chen W, Pan K, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Lu Y, You W, Xie Y.

Breast Cancer Res Treat. 2009 Sep;117(1):55-60. doi: 10.1007/s10549-008-0066-6. Epub 2008 May 30.

PMID:
18512148
17.

Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer.

Foulkes WD, Stefansson IM, Chappuis PO, Bégin LR, Goffin JR, Wong N, Trudel M, Akslen LA.

J Natl Cancer Inst. 2003 Oct 1;95(19):1482-5.

PMID:
14519755
18.

Morphology of breast cancer as a means of triage of patients for BRCA1 genetic testing.

Farshid G, Balleine RL, Cummings M, Waring P; Kathleen Cuningham Consortium for Research into Familial Breast Cancer (kConFab).

Am J Surg Pathol. 2006 Nov;30(11):1357-66.

PMID:
17063074
19.

Prognostic significance of molecular classification of breast invasive ductal carcinoma.

Muñoz M, Fernández-Aceñero MJ, Martín S, Schneider J.

Arch Gynecol Obstet. 2009 Jul;280(1):43-8. doi: 10.1007/s00404-008-0867-1. Epub 2008 Dec 11.

PMID:
19082617
20.

Breast infiltrating ductal carcinoma: analysis of hormone, HER-2 receptors and Ki-67 proliferation marker.

Mustać E, Zamolo G, Petković M, Dordević G, Radić J, Grgurević E, Batinac T.

Coll Antropol. 2008 Sep;32(3):741-6.

PMID:
18982746

Supplemental Content

Support Center